CRN president and CEO Steve Mister laid out four priorities for the supplement industry at a meeting yesterday. Among the highlights were to prepare for state based regulations and strengthening self regulation.
By By Steve Mister, President & CEO, Council for Responsible Nutrition
We all want an expedient solution to the stalemate with FDA over the legal status of cannabidiol (CBD), but the call to allow FDA to set a maximum safe level for CBD is antithetical to the law governing dietary supplements, DSHEA.
Nuseed Nutritional US has announced its omega-3 ingredient derived from a genetically modified canola strain has successfully completed a New Dietary Ingredient Notification with FDA.
FDA has issued an import alert on a Southeast Asian herb that reportedly has been used in a similar way to kratom, about which the Agency has also raised a red flag.
The publication of a recent FDA priorities list that omitted the hemp/CBD question is a reminder that a legislative solution is the only practical way forward for a regulatory resolution for these ingredients, advocates say.
Publishing a revised version of the NDI Draft Guidance has made a list of FDA priorities for the coming year. Industry observers welcomed the news, but questioned how much impact it might have if enforcement priorities remain as they are.
The Council for Responsible Nutrition has filed a citizen’s petition with FDA requesting that the Agency reverse its decision that the ingredient NAC is not legal for use in dietary supplements. CRN states that FDA’s ruling on the matter, voiced in warning...
Proposed modernizations to the Dietary Supplement Health and Education Act (DSHEA) and solutions to the CBD issue require “an outstanding effort by industry to speak with a united voice”, says Loren Israelsen, President of the United Natural Products...
The Hemp and Hemp-Derived CBD Consumer Protection and Market Stabilization Act represents ‘the best way’ to deal with the hemp-CBD issue for dietary supplements, says CRN’s Steve Mister, and once that’s clarified then the FDA and industry can address...
A recent paper claims FDA is in the dark as to how many new ingredients have come onto the market via the GRAS process. Only limited progress has been made in the decade since a Congressional report first raised the issue and directed the Agency to make...
Efforts to move the needle on hemp-CBD at the Federal level are slow, and upcoming exits of key personnel at FDA are unlikely to affect progress much, says NPA’s Dr Daniel Fabricant. “In some ways I think FDA likes the status quo,” he tells NutraIngredients-USA.
The US Food and Drug Administration has issued an import alert and seized products from two firms that were deemed to be offering New Dietary Ingredients that have not gone through the notification process.
Dr Cara Welch will step in as the acting director of the Office of Dietary Supplement Programs (ODSP) at the FDA from March 15, as Steven Tave accepts a new role as director of the Office of Strategic Planning and Operational Policy.
New users of dietary supplements – and increased usage among established consumers – are predicted to stay with the category after the pandemic subsides, according to industry CEOs.
There’s still time to register for the NutraIngredients-USA Business Leaders Forum to hear directly from the CEOs of some of the industry’s leading companies in a wide-ranging, interactive, and FREE webinar on NutraIngredients-USA.
